Critical Conversations: TIL Webinar Series

Watch HOPA's Collaboration with the Oncology Nursing Society (ONS) with the TIL Therapy On-Demand Bundle

Filling the Gap in Professional Knowledge Sharing

In mid-February 2024, the Food and Drug Administration approved the world's first ever tumor-infiltrating lymphocyte (TIL) therapy for people with advanced melanoma. Along with its success comes a fast-growing demand for patient access and the development of new TIL therapy sites. Currently, there are gaps in providing TIL therapy. There are also gaps in professional knowledge-sharing.

This collaboration between HOPA and ONS is an effort to demonstrate how two organizations can learn together to better understand the logistics of bringing TIL therapy to patients who might benefit from this treatment.

Three Webinars with Three Insights to TIL Therapy

These webinars will offer "behind the scenes" views to TIL therapy. Each webinar will be curated with different content, presented by HOPA and ONS members who will offer their unique vantage points.

Each webinar is 60 minutes in length, and the bundle offers 2.0 ACPE CE credits in total.

Register for the On-Demand Bundle here

Registration - offered at no cost - is now open.

The TIL Therapy On-Demand Webinar Bundle includes:

Webinar 1: Implementation and Adoption for TILs Therapy in a Cancer Program

Tumor-infiltrating lymphocyte (TIL) therapy is a form of immunotherapy that leverages a patient's immune system to combat cancer. The treatment involves isolating T cells from a patient's tumor, expanding their numbers in a laboratory setting, and reintroducing them into the patient to target and destroy cancer cells. This session will review operational best practices for adopting a TIL therapy program. We will review legal considerations, Information Security, nurse education, hospital administration, pharmacy considerations and therapeutics, stakeholder analysis, and physician leadership considerations utilizing a panel of experts through a moderator-led panel.

There are no CE credits on offer for this session.

Webinar 2: Keep Working TIL We Beat Melanoma! The Operations and Science Behind TIL Therapy

Join us for a panel discussion regarding FDA-approved TIL therapy for melanoma. We will discuss the mechanism of action and toxicities of TIL therapy, LD chemo, and IL-2. Additionally, we'll review logistics for scheduling resections, out of specification products, best practices for safely administering IL2, pharmacy logistics for IL2, and where TILs may be in the future.

There is 1.0 ACPE CE credit available for this session.

Webinar 3: Essential Steps for Navigating the Tumor-Infiltrating Lymphocyte (TIL) Journey in Melanoma: Common Obstacles, Logistical Considerations, Multidisciplinary Approaches, and Best Practices Throughout the Journey of TIL Therapy

Advancements in cancer treatment have led to the first FDA-approved cellular therapy product to treat solid tumors. This tumor-infiltrating lymphocyte (TIL) therapy has been added to the treatment armamentarium for patients with metastatic melanoma at a critical point in their cancer journey. As this exciting treatment option becomes reality, institutions can face many challenges as they attempt to integrate this new therapy into current practices. This panel session will explore the TIL journey from initial evaluation through hospitalization and supportive care. We will discuss common obstacles, logistical considerations, multidisciplinary approaches, and best practices associated with the TIL process.